The testosterone–SHBG ratio also exhibited a significant association with breast cancer risk in the placebo group (trend 1.21, 95% CI 1.05 to 1.41, p= 0.011) but not in the anastrozole group. This evidence concerns the gene SHBG and breast carcinoma.